Verrow Pharmaceuticals
Verrow Pharmaceuticals was founded in 2005 to commercialize Dr. Rowe’s discovery that SBECD, a substituted clyclodextrin, previously thought to be a purely inert solubilizer of poorly soluble pharmaceuticals for IV injection, that it was nephorprotective when compbined with a variety of kidney toxic agents and drugs including aminoglycosides, cancer agents such as IV mehtotrexate and cisplatin, and the iodinated contrast agents. that are used in imaging procedures used in interventional cardiology and neuroimaging and all imaging using x-rays. Kidnye damage from